Clinical data | |
---|---|
Trade names | Gynodian Depot (with estradiol valerate) |
Synonyms | DHEA enanthate; Prasterone heptanoate; DHEA heptanoate; DHEA-E; EDHEA; Androst-5-en-3β-ol-17-one 3β-heptanoate |
Routes of administration |
Intramuscular injection |
Drug class | Androgen; Anabolic steroid; Androgen ester; Estrogen; Neurosteroid |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Duration of action | 18 days |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C26H40O3 |
Molar mass | 400.60 g·mol−1 |
3D model (JSmol) | |
|
|
|
Prasterone enanthate (also known as prasterone heptanoate, dehydroepiandrosterone enanthate, DHEA enanthate, DHEA-E, or androst-5-en-3β-ol-17-one 3β-heptanoate) is a synthetic, injected, long-lasting ester prodrug of dehydroepiandrosterone (DHEA), a weak androgen and neurosteroid. It is a component of Gynodian Depot, a combination formulation of 4 mg estradiol valerate and 200 mg prasterone enanthate in oil for depot intramuscular injection that is used in the treatment of menopausal symptoms and is marketed in Europe and South America. Prasterone enanthate has an average duration of 18 days in this formulation. The drug was patented, by Schering, in 1971.